Sygnature Discovery Launches Strategic Brand Relaunch and New Website

Sygnature Discovery, a drug discovery contract research organisation (CRO), has announced a strategic brand relaunch, including the launch of a new website, cementing its position as a global drug discovery partner. The new identity highlights the company's truly integrated approach and positions Sygnature Discovery as the only provider of its kind across Europe and North America.

For more than 20 years, Sygnature Discovery has built a strong reputation for delivering high quality candidates. Continued investment and strategic acquisitions have enabled the company to support customers across the full drug discovery process, from target identification to candidate nomination.

Uniquely positioned as the only contract research organisation offering full Design, Make, Test, Analyze (DMTA) capabilities under one roof in both North America and Europe, Sygnature is now targeting increased awareness and market share on a global scale.

Over recent years, Sygnature Discovery has integrated several complementary businesses, strengthening its scientific breadth, scale and geographic footprint. Today, its capabilities span bioscience, protein science and structural biology, synthetic and medicinal chemistry, computer-aided drug design, drug metabolism and pharmacokinetics (DMPK), in vivo pharmacology, and form and formulation, all delivered through co-located, multidisciplinary teams.

The CEO stated that the company has grown significantly in scale and capability over the past two decades. Biotech and pharma companies are facing volatile investment conditions, tighter timelines and rising costs. The company's truly integrated approach is built around helping customers navigate that reality — whether they're outsourcing a whole programme or need expert input in a single discipline.

By bringing together multidisciplinary expertise in co-located teams, supported by AI and automation, the company helps customers move faster and improve the quality of their decisions. Across Europe and North America, Sygnature acts as an extension of customers' teams, delivering a service they can trust.

The company has 700 plus scientists from over 50 countries, working as one across Europe and North America. With no competing internal programs, the company offers total confidentiality and commitment.

Over the past 20 years, Sygnature Discovery has earned a track record of real impact: 60 plus advanced candidates, 200 plus patents filed, 200 plus active projects. Over 90 per cent of customers choose to stay with the company from biotechs racing to clinic to pharmaceutical companies that need specialised expertise for targeted challenges.

The company's team includes 400 pharmaceutical industry-experienced research scientists, over 80 per cent PhD qualified.